FDA Approves T-DXd for Two Early HER2-Positive Breast Cancer Settings
May 16, 2026
View online
FDA Approves T-DXd for Two Early HER2-Positive Breast Cancer Settings
OncoDaily Family is Growing: Launching Our New Radiotherapy Platform
Herbert Loong: OncoDaily Grand Rounds at ASCO26 – Sarcoma Edition
FDA approved Atezolizumab for adjuvant treatment of MDR–positive MIBC
20 Posts Not To Miss From ESMO Breast Cancer Congress 2026
Nearly Half of Older Adults With Metastatic NSCLC Never Received Systemic Therapy
M. Carmen Rubio Rodríguez Elected President-Elect Of ESTRO
Gevorg Tamamyan: Happy Birthday OncoDaily
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
